natgillin/translations-raw huggingface dataset:
A further aspect of the invention relates to the use of a 1-amino-alkylcyclohexane derivative (e.g., neramexane) for the manufacture of a medicament for treatment of an individual diagnosed with hearing loss. 
Uporaba nerameksana ili njegove farmaceutski prihvatljive soli za proizvodnju lijeka za liječenje ili prevenciju tinitusa, naznačena time da se liječenje provodi unutar tri do dvanaest mjeseci od početka tinitusa (subakutni tinitus).
at least a binary input (2) adapted to receive one or more candidate signals (Sc); 
najmanje binarni ulaz (2), prilagođen za primanje jednog ili više kandidatnih signala (S.);
Use of at least one ground natural calcium carbonate having a volume median diameter d 50 of between 0.05 and 0.3 µm, in a coating composition having a PVC in the range of from 5 % up to the CPVC and comprising at least one pigment having a refractive index of greater than or equal to 2.5, and at least one resin. Use according to claim 13, characterised in that the gloss and/or opacity of the composition applied to a substrate is equal to or greater than the gloss and/or opacity of a composition wherein the SMGCC is fully replaced by said pigment having a refractive index of greater than or equal to 2.5. 
Uporaba najmanje jednog usitnjenog prirodnog kalcijevog karbonata koji ima d50 (Mal) između 0.05 i 0.3 um, u sastavu za oblaganje koji obuhvaća barem jedan pigment indeksa refrakcije većeg od ili jednakog 2.5, sastava je jednaka ili veća od sjaja i/ili neprozirnosti istog sastava uvođenjem navedenog pigmenta indeksa refrakcije većeg od ili jednakog 2.5 na mjesto navedenog usitnjenog kalcijevog karbonata koji ima d50 između 0.05 10.3 um.
The compound according to claim 1, wherein the compound is: 
Spoj prema zahtjevu 1, naznačen time, da je odabran iz skupine koju čine:
expression of one or more functional neural markers; 
- < ekspresiju jednog ili više funkcionalnih neuronskih markera;
Glidants applied during pelletization include e.g. 
Glidanti koji se mogu primijeniti tijekom granuliranja su npr.
In a further preferred embodiment, the spore in the aforementioned method is selected from the group consisting of B. subtilis, B. amyloliquefaciens, B. licheniformis, B. megaterium, and B. pumilus; and the germinative compound in the aforementioned method is selected from the group consisting of L-alanine, L-valine, and L-asparagine. 
Smjesa sukladno zahtjevu 1, naznačeno time, da su spore odabrane iz skupine koju čine B. subtilis, B. amyloliquefaciens, B. licheniformis, B. megaterium, i B. pumilus; a L-aminokiselina je odabrana iz skupine koju čine L-alanin, L-valin, i L-asparagin.
The pharmaceutical composition of at least one of the claims 1-8 for use in treating at least one metabolic syndrome and/or atherosclerosis. 
Farmaceutski pripravak za uporabu prema barem jednom od zahtjeva 1-11, naznačen time što dijabetes je dijabetes tipa 2.
ocular diseases or disorders selected from glaucoma, retinopathy, diabetic retinopathy, blepharitis, dry eye syndrome, Sjögren's Syndrome; 
očnim bolestima ili poremećajima odabrani među glaukomom, retinopatijom, dijabetičkom retinopatijom, blefaritisom, sindromom suhog oka, Sjögrenovim sindromom;
wherein the ratio of the RP diastereomer to the SP diastereomer is at most 1:20. 
[image] gdje odnos (S) epimera prema (R) epimeru je najmanje 20:1.
The preferred fragrances for use in the present invention are Fragrance SZ-2108 and Fragrance SZ-1405 available from Sozio, Inc... 
Poželjni mirisi za upotrebu u ovom izumu su miris SZ-2108 i miris SZ-1405 dostupan od Sozio, Inc.
Self-propelled craft according to claim (1), characterized in that said craft has a mechanical element with two possible and distinct positions, and one or several fluid detection devices. 
Samohodno plovilo skladu s patentnim zahtjevom 1, naznačeno time, da navedeno plovilo ima mehanički element s dva moguća i različita položaja, te jedan ili više uređaja za otkrivanje tekućine.
A pharmaceutical composition comprising, together with a pharmaceutically acceptable carrier or diluent, the compound according to any one of Claims 1 to 9, or a pharmaceutically acceptable salt thereof; and an anticancer agent selected from the group consisting of anticancer alkylating agents, anticancer antimetabolites, anticancer antibiotics, plant-derived anticancer agents, anticancer platinum-coordinatedcomplex compounds, anticancer camptothecin derivatives, anticancer tyrosine kinase inhibitors, monoclonal antibodies, biological response modifiers, and other anticancer agents, wherein the definition of each anticancer agent is the same as defined in Claim 15, or a pharmaceutically acceptable salt thereof. 
Farmaceutski pripravak koji sadrži, zajedno s farmaceutski prikladnim nosačem ili punilom, spoj prema bilo kojem od zahtjeva 1 do 15, ili njegovu farmaceutski prikladnu sol ili ester; i citostatik odabran iz grupe koju čine alkilirajući citostatici, antimetaboliti citostatici, citostatici antibiotici, biljni citostatici, platinom-koordinirani kompleksni spojevi citostatici, citostatici derivati kamptotecina, citostatici inhibitori tirozin kinaze, monoklonska protutijela, modulatori biološkog odgovora, i drugi citostatici, gdje je definicija svake vrste citostatika kako je dano u zahtjevu 20, ili njihovu farmaceutski prikladnu sol ili ester.
placing in a cooperating manner the connecting means (13-29) and the wire ends (4, 6) into the receiving area (46); 
(d) stavljanje na kooperativan način sredstva za spajanje (13-29) i krajeva žice (4, 6) u mjesto za prihvat (46);
The compound for use according to claim 15 wherein the disease or condition is prostate cancer. 
Spoj za uporabu prema patentnom zahtjevu 15 naznačen time što bolest ili stanje je rak prostate.
HuLuc63, said HuLuc63 being a humanized IgG1 antibody having a heavy chain variable region corresponding to SEQ ID NO:5 and a light chain variable region corresponding to SEQ ID NO:6, for use in the treatment of multiple myeloma of a human patient, wherein the HuLuc63 is administered in combination with bortezomib, and wherein HuLuc63 is administered as an intravenous infusion at a dosage from 2.5 mg/kg to 20 mg/kg and the bortezomib is administered as an intravenous infusion at a dosage from 0.2 mg/m2 to 2.0 mg/m2. 
Hul_uc63, pri čemu je taj HuLuc63humanizirano IgG1 antitijelo koje ima jednu varijabilnu regiju teškog lanca koja odgovara sekvenci SEQ ID NO:5 i jednu varijabilnu regiju lakog lanca koja odgovara sekvenci SEQ ID NO:6, za primjenu u liječenju multiplog mijeloma, pri čemu se lenalidomid treba davati istovremeno, prije ili nakon davanja HuLuc63. Hul_uc63 i lenalidomid prema zahtjevu 6, pri čemu se HuLuc63 nalazi u prvom farmaceutskom pripravku a lenalidomid se nalazi u drugom farmaceutskom pripravku.
A compound of formula (I) wherein: 
Spoj, naznačen time, da ima formulu (I):
Method for grafting propagation materials of grapevines and similar plant varieties, comprising a manual loading step, in which the elements to be grafted are loaded manually, a heeling step and a milling step in which the elements to be grafted are cut, a grafting step in which the cut elements are inserted into search other, and a step in which the thus completed graft is unloaded, characterized in that the loading step and the heeling step are carried out in two mutually opposing and axially aligned stations, whereas the milling step is carried out in a sequence by having the elements to be grafted (12, 13) displaced with the help of moving means capable of moving on a horizontal plane. 
HR P20120663 T1 PATENTNI ZAHTJEVI Postupak za okuliranje reznica vinove loze 1 sličnih biljnih sorti, koji se sastoji od koraka ručnog umetanja, gdje se ručno umeću elementi koji se cijepe, koraka zarezivanja u obliku pete i koraka rezanja u kojem se elementi koji se cijepe režu, koraka cijepljenja u kojem se odrezani elementi umeću jedan u drugi, te koraka u kojem se tako dovršeni kalem istovaruje, naznačen time da se korak umetanja i korak zarezivanja u obliku pete provode na dvije međusobno nasuprotne i aksijalno raspoređene postaje, dok se korak rezanja provodi slijedno tako da su elementi koji se cijepe (12, 13) istiskuju pomoću pokretnih sredstava koja se mogu kretati u horizontalnoj ravnini.
The method of claim 1, wherein the lipids comprise a cationic lipid, a neutral lipid, a sterol, and a polyethylene (PEG)-lipid conjugate, wherein the lipids optionally further comprise a targeting lipid selected from the group consisting of folic acid, vitamin E, compounds of the following formula (A) and compounds of the following formula (B): 
Postupak prema zahtjevu 1, naznačen time što lipidi obuhvaćaju kationski lipid, neutralni lipid, sterol te konjugat polietilen (PEG)-lipid, pri čemu lipidi po izboru nadalje sadrže ciljajući lipid odabran iz skupine koju čine folna kiselina, vitamin E, spojevi sljedeće formule (A) i spojevi sljedeće formule (B): L-X-R
The method of claim 1, wherein the therapeutically effective amount of crenolanib or a pharmaceutically acceptable salt thereof is administered up to three times or more a day for as long as the subject is in need of treatment for the hematologic malignant proliferative disorder. 
Pripravak namijenjen uporabi u skladu s patentnim zahtjevom 1, pri čemu se terapeutski djelotvorna količina crenolaniba ili njegove farmaceutski prihvatljive soli daje tri ili više puta dnevno sve dok je subjektu potrebno liječenje akutne mijeloične leukemije (AML).
The compound or salt of claim 1, wherein R8 is hydrogen, fluorine, or methyl. 
Spoj ili sol u skladu s patentnim zahtjevom 1 ili 9, naznačen time što je R* vodik, fluor ili metil.
Step 1: reacting an acyl chloride of formula (III) with an alkyl benzene of formula (IV) to yield the corresponding compound (V): 
navedeni proces sadrži korake: korak 1: reakcija acil klorida formule (III) s alkil benzenom formule (TV) da se dobije odgovarajući spoj (V):
The nucleic acid of claim 1, wherein the variant ActRIIB protein comprises a K at the position corresponding to position 64 of SEQ ID NO: 2. 
Varijantni ActRIIB protein iz bilo kojeg od prethodnih zahtjeva, naznačen time, što protein sadrži D ili E na poziciji koja odgovara poziciji 79 SEQ ID NO:2.
A counter as claimed in claim 1 further comprising a coupling mechanism for releasably coupling said first ring member to said second ring member, to allow said first and second ring members to rotate cooperatively when coupled and to allow independent rotating of said first ring member when not coupled. 
pokretački mehanizam (205) za rotiranje navedenog prvog prstenastog člana; i mehanizam (700) za uparivanje za oslobađajuće uparivanje navedenog prvog prstenastog člana sa navedenim drugim prstenastim članom, da bi se omogućilo navedenom prvom i drugom prstenastom članu da se rotiraju kooperativno kada su upareni i da bi se omogućilo nezavisno rotiranje navedenog prvog prstenastog člana kada nije uparen;
acetic acid containing 0.9% sodium chloride adjusted to pH 4.0 with sodium hydroxide. The compound of the invention is dispersed in the alcohol and dissolved in the propylene glycol by the aid of heat. 
2-hidroksipropil-B-ciklodekstrina u 50 mM do zasićenja octenoj kiselini s 0,9 % natrijevog klorida, podešeno natrijevim hidroksidom do pH 4,0 100 ml Spoj prema ovom izumu dispergira se u alkoholu, te otopi u propilen-glikolu uz grijanje.
A method according to claim 33, wherein said heterogeneous catalyst comprises said at least one surface area stabilizer in an effective amount up to 20 % by weight, such as an effective amount up to 10 % by weight, preferably said surface area stabilizers in an effective amount up to 7,5 % by weight, such as surface stabilizers in an effective amount up to 5 % by weight, and more preferably said surface stabilizers are present in an effective amount from 0,5-5 % by weight, such as 1-3 % by weight. 
Metoda u skladu s patentnim zahtjevom 33, pri čemu navedeni heterogeni katalizator obuhvaća navedeno barem jedno površinsko područje stabilizatora u učinkovitoj količini do 20 % prema težini, kao što je učinkovita količina do 10 % prema težini, poželjno je navedeno površinsko područje stabilizatora u učinkovitoj količini do 7,5 % prema težini, kao što su površinski stabilizatori u učinkovitoj količini do 5 % prema težini, a još poželjnije su navedeni površinski stabilizatori prisutni u učinkovitoj količini od 0,5-5 % prema težini, kao što je 1-3 % prema težini.
is selected from hydrogen and methyl; when R2 is hydrogen then 
R? je izabran od vodik i metil; kada R? je vodik onda
A compound of the Formula (I) wherein: 
Spoj s formulom (I) naznačen time da:
a step of retrieving, from the matching record, the personal identification number (210) associated with said received request code (260) and 
korak dohvaćanja osobnog koda (210) povezanog sa navedenim kodom zahtjeva 260,te
A pharmaceutical or veterinary composition comprising a compound according to claim 1 or 2 and at least one pharmaceutically acceptable carrier. 
Farmaceutski ili veterinarski pripravak, naznačen time što sadrži spoj u skladu s patentnim zahtjevom 1 ili 2, kao i najmanje jednu farmaceutski prihvatljivu podlogu.
The method of claim 1, wherein step 1c) comprises the further step of creating a k x m-Beta random number matrix (Beta), wherein said m elements of the first data-set are represented by an m-element column vector (VA) and said k encoded elements are represented by a k-element column vector (VY), which is computed by performing the matrix multiplication of the Beta random number matrix and the m-element column vector; wherein prior to performing step 1f) each of the k encoded elements is encapsulated along with the entries of the respective row of the Beta random number matrix into a separate packet to be transmitted; and wherein step 1g) comprises the step of computing the inverse of said received Beta random number matrix, wherein the m-element column vector is computed by performing the matrix multiplication of the inverse of said Beta random number matrix and the k-element column vector. 
Postupak u skladu s patentnim zahtjevom 1, naznačen time što korak 1c) uključuje dodatni korak generiranja k x m-Beta matrice slučajnih brojeva (Beta), gdje navedenih m elemenata prvog podatkovnog niza predstavlja vektor stupca m-elemenata (Vx), a navedenih k kodiranih elemenata predstavlja vektor stupca k elemenata (Vy), što se izračunava matričnim množenjem Beta matrice slučajnih brojeva s vektorom stupca m-elemenata; gdje se prije provedbe koraka 1f) svaki od k kodiranih elemenata učahuruje uz članove odgovarajućeg reda Beta matrice slučajnih brojeva u odvojeni paket kojeg treba predati; te gdje korak 1g) uključuje korak izračunavanja inverzije navedene primljene Beta matrice slučajnih brojeva, gdje se vektor stupca m-elemenata izračunava matričnim množenjem inverzije navedene Beta matrice slučajnih brojeva s vektorom stupca k elemenata.
The coffin according to one or more of the preceding claims, characterized in that the covering film comprises a certification element that is associated with it and is suitable to be applied to one face or the other of said covering film or within said covering film. 
Mrtvački kovčeg prema jednom ili više od prethodnih zahtjeva, naznačen time, da obložna folija sadrži u sebi certifikacijski element koji je pogodan za postavljanje na obje površinske strane spomenute zaštitne folije ili unutar spomenute zaštitne folije. HR P20120783 T1
• disable operation of said machine (1) as long as incompatibilities are detected; 
* onemogući upravljanje navedenom strojem (1) dok god su nekompatibilnosti detektirane;
In order to minimise this type of inconvenience, the collar (2) used in the first two embodiments of the invention should be preferably made of aluminium or steel, resulting in considerable production costs. 
Da bi se smanjila na najmanju mjeru ova vrsta neprijatnosti, poželjno je da okvir (2) u prva dva ostvarenja ovog izuma bude načinjen od aluminija ili čelika, što ima za posljedicu znatne troškove proizvodnje.
According to a further feature of this aspect of the invention there is provided a method for treating a cancer (for example a cancer selected from leukaemia, multiple myeloma, lymphoma, bile duct, bone, bladder, brain/CNS, breast, colorectal, endometrial, gastric, head and neck, hepatic, lung, neuronal, oesophageal, ovarian, pancreatic, prostate, renal, skin, testicular, thyroid, uterine and vulval cancer) in a warm-blooded animal, such as man, in need of such treatment, which comprises administering to said animal an effective amount of a quinazoline derivative of the Formula I, or a pharmaceutically-acceptable salt thereof, as defined hereinbefore. 
Prema dodatnoj značajci ovog aspketa, objavljen je postupak za liječenje raka (na primjer, leukemije, multiplog mijeloma, limfoma, žuči, kosti, mjehura, mozga/CNS-a, grudi, kolorektalnog, endometrialnog, gastričkog, glave i vrata, hepatičkog, plućnog, neuronalnog, ezofagalnog, jajnika, pankreasa, prostate, bubrežnog, kože, testikularnog, tiroidnog, uterinug i vulvarnog raka) u toplokrvnoj životinji, poput čovjeka, kojoj je takvo liječenje potrebno, a koji se sastoji od davanja spomenutoj životinji efektivne doze derivata kinazolina prikazanog Formulom I ili njegove farmaceutski prihvatljive soli, u skladu sa definicijom u gornjem tekstu.
The method of claim 1, wherein the isolated antibody, or antigen-binding fragment thereof, binds to human C5 at pH 7.4 and 25° C. with an affinity dissociation constant (KD) that is in the range 0.1 nM≤KD≤1 nM. The method of claim 1, wherein the antibody, or antigen-binding fragment thereof, binds to human C5 at pH 6.0 and 25° C. with a KD≥10 nM. 
Izolirano antitijelo, ili njegov fragment koji se veže na antigen, u skladu s bilo kojim od prethodnih patentnih zahtjeva, naznačeno time, da se antitijelo ili njegov fragment koji se veže na antigen: (i) veže na ljudski C5 pri pH 7,4 i 25 °C s konstantom afiniteta disocijacije (KD) u rasponu od 0,1 nM ≤ KD ≤ 1 nM ili (ii) veže na ljudski C5 pri pH 6,0 i 25°C uz KD ≥ nm.
The rodent of claim 1, wherein the human Va and Ja segments rearrange to form a rearranged human Va/Ja sequence and/or the human VB, DB, and JB segments rearrange to form a rearranged human VB/DB/JB sequence. 
Glodavac prema zahtjevu 1, naznačen time, da se ljudski Va- i Ja-segmenti rearanžiraju za tvorbu rearanžirane ljudske Va/Ja-sekvence i/ili se ljudski segmenti VB, DB i JB rearanžiraju za tvorbu rearanžirane ljudske VB/DB/JB-sekvence.
A cement according to any of the above claims 1-2, wherein the calcined clay is produced by heat-treating clay separate from the other constituents of the clinker replacement material at a temperature sufficient to a) dehydroxylate the clay to a chrystallographically amorphous material, and b) prevent the formation of high temperature alumino-silicate phases such as mullite. 
Cement prema bilo kojem od prethodnih zahtjeva, naznačen time što je glineni materijal proizveden od gline koja se sastoji od najmanje 90 % m/m glinenih minerala koji pripadaju skupini kaolina, ili skupini smektita, ili skupini vermikulita, ili njihovim smjesama.
A cellulose fibre-based support according to claim 1, 2 or 3, characterized in that said organic molecule is undecylenic aldehyde. 
Podloga na bazi celuloznih vlakana u skladu s patentnim zahtjevom 1, 2 ili 3, naznačena time, da je spomenuta organska molekula undeciklenički aldehid.
Binding assay was performed in 96 well flat bottom plate and initiated by mixing 10.6 µg protein/well with solutions of standard compounds or test compounds (final concentrations 0-10 µM) and 1 nM final concentration of 3H-ZM241385 (R1036 from Tocris). 
Ispitivanje vezanja se izvodu na ploči sa 96 jažica s ravnim dnom i inicira miješanjem 10.6 ug proteina/jažici sa otopinom standardnih spojeva ili ispitivanih spojeva (završna koncentracija 0-10 uM) i 1 nM završne koncentracije od *H-ZM241385 (11036 od Tocris).
A synergistic combination for use according to any one of the preceding claims, wherein said antibody specific for CD19 and Ibrutinib are administered separately. 
Sinergistička kombinacija za uporabu u skladu s bilo kojim od prethodnih patentnih zahtjeva, naznačena time što se navedeno antitijelo specifično za CD19 i ibrutinib primjenjuju odvojeno.
The aerosol of claim 3, having a mass median aerodynamic diameter from about 2 microns to about 5 microns with a geometric standard deviation less than or equal to about 2.5 microns, preferably from about 2.5 microns to about 4.5 microns with a geometric standard deviation less than or equal to about 1.8 microns, more preferred from about 2.8 microns to about 4.3 microns with a geometric standard deviation less than or equal to about 2 microns; and wherein the cation is a divalent cation. 
Aerosol iz patentnog zahtjeva 3, ima aerodinamični promjer srednje mase od oko 2 mikrona do oko 5 mikrona s geometrijskim standardnim odstupanjem manjim od ili jednakim s oko 2,5 mikrona, preporučljivo od oko 2,5 mikrona do oko 4,5 mikrona s geometrijskim standardnim odstupanjem manjim od ili jednakim s oko 1,8 mikrona, još preporučljivije od oko 2,8 mikrona do oko 4,3 mikrona s geometrijskim standardnim odstupanjem manjim od ili jednakim s oko 2 mikrona; i pri čemu je kation dvovalentni kation.
The composition of claim 11 wherein said pharmaceutically acceptable salt is a hydrochloride salt, methanesulfonate, toluenesulfonate, acetate, succinate, citrate, maleate, tartrate, or mixtures thereof, preferably an acetate salt. 
Sastav prema zahtjevu 11, naznačeno time da je spomenuta farmaceutski prihvatljiva sol hidrokloridna sol, metan sulfonat, toluensulfonat, acetat, sukcinat, citrat, maleat, tartrat, ili mješavina istih, poželjno sol acetata.
The number of balance beams is not limited. 
Broj objave europskog patenta:
(a3) an antibody H chain consisting of the amino acid sequence having at least 70% sequence identity with amino acid sequence of SEQ ID NO: 3; 
(a3) H-lanac protutijela koji se sastoji od aminokiselinske sekvence SEQ ID NO: 3;
According to an exemplary embodiment of the present invention, the self-binding particle suspension obtainable by the inventive process is used in paper, e.g., in wet end process of a paper machine, preferably in cigarette paper and/or coating applications, or preferably as support for rotogravure and/or offset and/or digital printing. 
Uporaba prema zahtjevu 23, gdje se suspenzija samoljepljivih pigmentnih čestica koristi u procesu vlažnog kraja papirnog stroja, za cigaretni papir i/ili primjene u oblaganju, ili kao potpora za rotogravuru i/ili offset i/ili digitalni tisak.
expressing the recombinant nucleic acids of steps (b) and (c); wherein the secretion rate of the recombinantly expressed VKD protein is substantially increased when compared to the expression of the rVKD protein in a host organism which does not co-express rVKORC1. 
(c) eksprimiranje nukleinskih kiselina iz koraka (a) i (b); pri čemu se količina sekrecije rekombinantno eksprimiranog VKD-proteina uglavnom povećava u usporedbi s ekspresijom rVKD-proteina u organizmu domačina, koji ne ko-eksprimira VKORC1.
transforming a eukaryotic cell with an expression vector comprising the recombinant nucleic acid of claim 6 to 9 or 14 or 15; and 
promjene eukariotske stanice s ekspresionim vektorom koji sadrži rekombinantnu nukleinsku kiselinu sukladno patentnom zahtjevu 6; i
and reacting said compound of formula (II) in said reaction vessel with a compound of the formula (III): 
Nk i stavljanjem u reakciju navedenog spoja formule (II) u navedenu reakcijsku posudu sa spojem formule (III);
The complex of claim 5, wherein the biologically active molecule or imaging agent is non-covalently bound to the carrier peptide. 
Kompleks prema zahtjevu 5, naznačen time da je biološki aktivna molekula ili kontrastno sredstvo nekovalentno vezano na peptid nosač.
wherein substituent group C, RD7, RD8, RD9, and Z are as defined in claim 1 . 
Z-C(RD7)(RD8)(RD9), (dok supstituentska skupina C, RD7, RD8, RD9, i Z, imaju isto značenje kao što su navedeni u zahtjevu 1).